The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature ArticleAirway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance
Section snippets
Introduction (by Paul M. O'BYRNE and Parameswaran Nair)
In 1945, Tiffeneau and Beauvallet1 reported, for the first time, the use of inhaled acetylcholine to measure airway responsiveness in patients with asthma. Subsequently, Curry2 demonstrated that patients with asthma developed bronchoconstriction after administration of intramuscular, intravenous, or nebulized histamine. This increased bronchoconstrictor response in patients with asthma was labeled “airway reactivity,” which was described as nonspecific, because the increased responses occurred
The Contributions of Airway Smooth Muscle to Airway Responsiveness (by James G. Martin)
Airway smooth muscle is the principal tissue mediating airway narrowing and not surprisingly has been a target of pharmacological therapy since the earliest times. Inhaled methacholine acts principally to cause airway narrowing by activation of muscarinic receptors on the smooth muscle of the airways. The degree of airway narrowing in response to stimulation of smooth muscle by methacholine and other bronchoconstrictive substances is a function of the force generated by the contracting muscle
Measurement of AHR (by Donald W. Cockcroft)
Airway hyperresponsiveness (AHR), an objective measure of variable airflow obstruction, is measured using provocation tests with chemical (histamine, methacholine, adenosine monophosphate [AMP], mannitol, etc) or physical (exercise or its surrogate eucapnic voluntary hyperpnea [EVH]) stimuli.21 Bronchoprovocation is recommended as a diagnostic investigation in subjects with symptoms (possibly asthmatic) and normal flow rates. Stimuli used to measure AHR have been categorized as direct or
Technical Factors in the Assessment of AHR (by Myrna Dolovich)
The assessment of AHR involves the inhalation of a challenge aerosol produced via liquid nebulization with a specific breathing pattern to administer the drug.41 These components are influenced by a number of technical factors that can alter the generation and delivery of aerosol to the lung. Although liquid aerosols of histamine and methacholine have been the choice pharmaceutic, recent developments have produced and successfully tested a dry powder formulation of methacholine, inhaled via a
Assessment of Airway Responsiveness to Manage Occupational Asthma (by Catherine Lemiere)
The diagnosis of occupational asthma (OA) requires a comprehensive investigation involving the performance of different and complementary tests. The assessment of airway responsiveness is crucial in the evaluation of a patient suspected of having OA. It should be performed at different stages of the investigation of OA: at the beginning of the investigation to confirm the diagnostic of asthma; during the investigation to confirm the relationship between the onset of asthma and the exposure to a
Assessment of AHR to Evaluate Exercise-induced Respiratory Symptoms (by Louis-Philippe Boulet)
Most subjects with asthma may experience a fall in expiratory flows after exercise, usually associated with respiratory symptoms.61 This may occur more frequently when asthma is not optimally controlled, or after exposure to sensitizing agents or respiratory infections. EIB results from smooth muscle contraction, associated with the release of mediators such as histamine, prostaglandins, and cys-leukotrienes and possibly neural (eg, cholinergic) influences.62, 63 The main trigger of EIB is
Assessment of AHR to Evaluate New Medications (by Paul M. O'BYRNE)
Measurements of methacholine AHR have been extensively used to evaluate the efficacy and duration of effect of functional antagonists, such as inhaled β2-agonists. Early studies compared functional antagonists with different mechanisms of action, such as theophylline and inhaled β2-agonists,83 different formulations of short-acting inhaled β2-agonists,84 and more recently short-acting β2-agonists compared with long-acting β2-agonists.85
Another important contribution of measuring methacholine
Assessment of AHR in a Severe Asthma Clinical Practice (by Parameswaran Nair)
AHR is a characteristic feature of asthma, and its measurement is an important tool in its diagnosis. As already discussed in this symposium, in addition to its utility to relate symptoms such as cough, wheeze, and shortness of breath to variable airflow obstruction (ie, to diagnose current asthma), the test is useful to make a number of other clinical assessments. These include (1) evaluation of patients with OA, (2) evaluation of patients with exercise-induced respiratory symptoms, (3)
References (117)
- et al.
Comparison of bronchial responses to prostaglandin F2 alpha and methacholine
J Allergy Clin Immunol
(1981) - et al.
Airway hyperresponsiveness and calcium handling by smooth muscle: a “deeper look”
Chest
(2002) - et al.
Mechanisms of airway remodeling
Chest
(2013) - et al.
Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma
J Allergy Clin Immunol
(2010) - et al.
Methacholine challenge: comparison of two methods
Chest
(2005) - et al.
Effect of challenge method on sensitivity, reactivity, and maximal response to methacholine
Ann Allergy Asthma Immunol
(2006) - et al.
Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations
J Allergy Clin Immunol
(2004) - et al.
The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result
J Allergy Clin Immunol
(2006) - et al.
Importance of evaporative water losses during standardized nebulized inhalation provocation tests
Chest
(1989) - et al.
Dose versus concentration of methacholine
Ann Allergy Asthma Immunol
(1999)
Sensitivity and specificity of histamine PC20 determination in a random selection of young college students
J Allergy Clin Immunol
Airway responsiveness to inhaled histamine in chronic obstructive airways disease: chronic bronchitis vs emphysema
Chest
Chronic cough: eosinophilic bronchitis without asthma
Lancet
Exercise in elite summer athletes: challenges for diagnosis
J Allergy Clin Immunol
Methacholine dry powder inhaler as a new tool for bronchial challenge test
Int J Pharm
A new nebuliser
Lancet
Standardization of bronchial inhalation challenge procedures
J Allergy Clin Immunol
Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation
J Allergy Clin Immunol
Diagnosis and management of work-related asthma: American College of Chest Physicians Consensus Statement
Chest
A systematic review of the diagnosis of occupational asthma
Chest
Predictive value of nonspecific bronchial responsiveness in occupational asthma
J Allergy Clin Immunol
Usefulness of induced sputum in investigating occupational asthma with normal responsiveness to methacholine: a case report
J Allergy Clin Immunol
Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter
Ann Allergy Asthma Immunol
Pathogenesis of exercise-induced bronchoconstriction
Immunol Allergy Clin North Am
Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma
Chest
Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5-year prospective follow-up study of 42 highly trained swimmers
J Allergy Clin Immunol
Airway hyperresponsiveness in elite swimmers: is it a transient phenomenon?
J Allergy Clin Immunol
The effect of theophylline and beta 2 agonists on airway reactivity
Chest
Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma
J Allergy Clin Immunol
Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber
J Allergy Clin Immunol
Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy
J Allergy Clin Immunol
The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma
J Allergy Clin Immunol
Epreuve de bronchoconstriction et de bronchodilation par aerosols
Bull Acad Med
The action of histamine on the respiratory tract in normal and asthmatic subjects
J Clin Invest
Effect of maximal respiratory manoeuvres on bronchial sensitivity of asthmatic patients as compared to normal people
Br Med J
Bronchial reactivity to inhaled histamine: a method and clinical survey
Clin Allergy
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction
J Appl Physiol
Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls
N Engl J Med
Functional significance of increased airway smooth muscle in asthma and COPD
J Appl Physiol
Airway smooth muscle, tidal stretches, and dynamically determined contractile states
Am J Respir Crit Care Med
Effects of lung volume on maximal methacholine-induced bronchoconstriction in normal humans
J Appl Physiol
The structure of large and small airways in nonfatal and fatal asthma
Am Rev Respir Dis
Airway smooth muscle hypertrophy and hyperplasia in asthma
Am J Respir Crit Care Med
Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression
Am J Respir Crit Care Med
Myosin, transgelin, and myosin light chain kinase: expression and function in asthma
Am J Respir Crit Care Med
Human trachealis and main bronchi smooth muscle are normoresponsive in asthma
Am J Respir Crit Care Med
The gain of smooth muscle's contractile capacity induced by tone on in vivo airway responsiveness in mice
J Appl Physiol
Direct and indirect challenges in the clinical assessment of asthma
Ann Allergy Asthma Immunol
Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma
Clin Allergy
Cited by (0)
The symposium was organized with an unrestricted educational grant from Methapharm Inc, Brantford, Ontario, Canada. P. Nair is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases.
Conflicts of interest: P. Nair declares that the report was based on a symposium that was supported by an unrestricted grant from Methapharm Inc; has received consultancy fees from AstraZeneca, Roche, Sanofi, Knopp, and Teva; has received research support from AstraZeneca, Teva, Novartis, Roche, Sanofi, Boehringer-Ingelheim, and GlaxoSmithKline; and has received lecture fees from AstraZeneca, Novartis, and Teva. J. G. Martin has received travel support from Methapharm and has received lecture fees from AstraZenenca. D. C. Cockcroft has received consultancy fees and travel support from Methapharm; is on the Methapharm Canada advisory board; is employed by the University of Saskatchewan; and has received research support from AllerGen and AstraZeneca. M. Dolovich has received consultancy fees from Methapharm and Teva and has received research support from Boehringer-Ingelheim. C. Lemiere has received fees for participation in Metafarm, GlaxoSmithKline, Teva, and AstraZeneca advisory boards and is a member of the Canadian Thoracic Society Asthma Clinical Assembly. L.-P. Boulet is on the advisory boards for and has received consultancy fees from AstraZeenca, Novartis, and Methapharm; has received research support from Altair, Amgen, Asmacure, AstraZeneca, Boehringer-Ingelheim, Boston Scientific, Genentech, GlaxoSmithKline, Novartis, Ono Pharma, Schering, and Wyeth; has received lecture fees from AstraZeneca, GlaxoSmithKline, Merck, and Novartis; received royalties from UpToDate; has received payment for the development of educational presentations from AstraZeneca, GlaxoSmithKline, Merck Frosst, Boehringer-Ingelheim, and Novartis; has received travel support from Novartis and Takeda; is a member of the Canadian Thoracic Society Respiratory Guidelines Committee; is Chair of GINA Guidelines Dissemination and Implementation Committee; and is Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. P. M. O'Byrne is on the Joint Oversight Board for Long-Acting β2-Agonists Safety Study; has received consultancy fees from AstraZenena, GlaxoSmithKline, Merck, and Boehringer-Ingelheim; and has received research support from AstraZeneca, Amgen, Genentech, and Axikin.
Report of the Frederick E. Hargreave Symposium on Airway Hyperresponsiveness, Hamilton, Ontario, Canada, August 6, 2016.